Hexarelin vs Ipamorelin: Which GH Peptide Fits Which Goal

If you searched “hexarelin vs ipamorelin,” you are probably choosing between the strongest GH secretagogue on the market and the cleanest one. I wrote a full hexarelin review yesterday covering its mechanism, its dosage range, and the cardiac question nobody answers well. This one is the head-to-head, and it is also the first time I have written about ipamorelin on its own.

Legal status first, because it decides the rest

Neither compound is FDA-approved for any indication. Both are sold as research chemicals, not medicine, and that framing is not a legal workaround, it is the actual regulatory status.

Ipamorelin has been worse off since October 2023, when the FDA placed it on the Section 503A Category 2 bulk drug substances list, the “may present significant safety risks” category. CJC-1295 landed on the same list at the same time. A Category 2 listing means a compounding pharmacy is not supposed to fill it, full stop, while that classification stands. As of this writing in September 2026, ipamorelin and CJC-1295 remain in active litigation over that placement, alongside AOD-9604 and thymosin alpha-1, and the FDA’s own timeline points to a final rule around February 2027. Until then, the Category 2 listing is still in effect. This is separate from the group of peptides the Pharmacy Compounding Advisory Committee actually voted on in July 2026, BPC-157, TB-500, and others, where 6 of 7 got a favorable recommendation over FDA staff’s own objection. Ipamorelin and CJC-1295 were not part of that vote.

Hexarelin’s compounding status is murkier. I could not find a documented Category placement for it specifically, and I am not going to guess at one. What is documented: it has never had an FDA-approved indication in humans, and there is no established legal compounding pathway for it in the US right now either way.

Both compounds sit under section S2 of the World Anti-Doping Agency’s Prohibited List, Peptide Hormones, Growth Factors, Related Substances, and Mimetics, banned both in and out of competition. If you compete in a tested federation, this section ends the conversation regardless of anything below it.

None of this is sold through Enhanced Labs. If you came here looking for a product link, there is not one.

What each one is

Both are growth hormone releasing peptides, GHRPs, which work by activating the ghrelin receptor, GHSR-1a, on the pituitary. That is the same receptor ghrelin itself uses, the hormone your stomach releases when you are hungry, which is why GHRPs also tend to increase appetite.

Hexarelin is a hexapeptide built in the early 1990s to be the strongest GHRP available. A human dose-response study using single IV doses in 12 men found it raised GH in a dose-dependent way, peaking at roughly 30 minutes and returning to baseline within 4 hours, with a GH-decline half-life around 55 minutes. It also activates a second receptor, CD36, found on heart muscle and on macrophages, a target its own designers did not aim for, and the source of the cardiac question I covered in yesterday’s piece.

Ipamorelin is a pentapeptide, 5 amino acids instead of 6, engineered a few years later specifically to fix hexarelin’s lack of selectivity. In the original 1998 characterization, it released GH about as strongly as GHRP-6 in an animal model, but at doses up to 200 times higher than what was needed for that GH release, it still did not raise ACTH or cortisol above what a GHRH challenge alone produced. That gap, GH goes up, the stress-axis hormones do not, is the entire reason ipamorelin exists as a separate compound rather than a hexarelin dosing tweak. A later human pharmacokinetic study, 40 healthy men given a single IV infusion, measured a terminal half-life of 2 hours, a single clean GH pulse peaking around 40 minutes, then an exponential decline back to baseline.

Head-to-head

Law 5: why you stack ipamorelin with a GHRH analog, not with another GHRP

I run on 5 laws of biochemistry physics, and the one that matters here is independent receptor stacking. Different receptors sit on independent signaling pathways. Hit 2 of them at once and the effects add up rather than compete for the same slot. Hit the same receptor twice with 2 different drugs, and you mostly get one drug’s effect with extra side-hormone noise from whichever one is less selective.

Ipamorelin and hexarelin both bind GHSR-1a. Stack them together and you are occupying the same receptor with 2 different keys, not opening 2 doors. A 1990 study in normal men showed something different and more useful, that combining a GHRP with GHRH itself produced a synergistic GH release, bigger than either compound alone at the same dose. GHRH works through its own receptor, GHRH-R, a completely separate signaling pathway from the ghrelin receptor. That is Law 5 in practice, 2 independent pathways converging on the same pituitary cell, additive rather than competitive.

CJC-1295 is a long-acting GHRH analog, and this is the mechanical reason the ipamorelin plus CJC-1295 stack shows up in every search bar next to “ipamorelin review.” A 2006 trial running 2 dose-escalation studies, 28 and 49 days, in healthy adults aged 21 to 61, found that a single CJC-1295 injection raised GH 2 to 10-fold for 6 or more days and IGF-1 1.5 to 3-fold for 9 to 11 days, with an estimated half-life of 5.8 to 8.1 days. After repeated dosing, IGF-1 stayed elevated above baseline for up to 28 days. That is a different pharmacokinetic shape entirely from ipamorelin’s 2-hour pulse, and stacking the 2 means a background elevation from the GHRH analog with a sharp, selective GH pulse layered on top from the GHRP, on 2 separate receptors.

Hexarelin plus a GHRH analog would follow the same additive logic, on paper. In practice you are then adding hexarelin’s cortisol, ACTH, and prolactin load on top of it, which is exactly the tradeoff that pushed me off hexarelin in the first place.

What the human trials looked at

The trials below describe what dose and schedule were actually tested in humans. That description is the evidence base itself.

The ipamorelin pharmacokinetic study used a 15-minute IV infusion at 5 escalating doses in 40 healthy men, and it was designed purely to characterize the GH pulse and clearance, not to test a therapeutic outcome. The one trial that did test an outcome was a phase 2, multi-center, randomized, double-blind, placebo-controlled study in 114 patients recovering from bowel resection surgery, given IV ipamorelin twice daily starting the day after surgery through day 7 or discharge. The endpoint was time to the first tolerated meal. Ipamorelin came in faster, 25.3 hours versus 32.6 hours for placebo, but the trial could not separate the groups statistically, p equals 0.15. Adverse events ran lower in the ipamorelin arm than placebo, 87.5% versus 94.8%, so the safety signal in that trial was clean even where the efficacy signal was not. That is the most rigorous human data ipamorelin has, and it is a null result on the primary endpoint. I am not going to paper over that.

Hexarelin’s human data is older and smaller, dose-response and pituitary-axis comparison studies from the 1990s in a dozen or 2 dozen men at a time, useful for characterizing what the compound does to circulating hormones, not built to test any clinical outcome at all.

Why I stopped running either of them daily

I ran hexarelin on a daily schedule long enough to watch the response curve I started with shrink. The literature on that desensitization lines up with what daily dosing produces at the receptor level, tolerance builds, and by 16 weeks of continuous daily use the GH response documented in the literature is roughly half of where it started. Add in a hormone that is also raising my cortisol and prolactin every single day, and the daily-dosing math stopped making sense to me well before the desensitization curve flattened all the way out.

Ipamorelin does not carry hexarelin’s cortisol and ACTH tax, which is the whole point of the molecule, but a short half-life and a receptor that downregulates with constant occupancy is still a receptor that downregulates with constant occupancy. I moved to a pulsed, cycled approach on both rather than running either one every day indefinitely, for the same underlying reason: a receptor you hit once and let recover responds differently than one you never stop hitting.

Who each one fits

If the goal is the single biggest acute GH pulse you can get from a GHRP and you have already accepted the cortisol, ACTH, and CD36 tradeoffs I covered in the hexarelin piece, hexarelin is built for that job and nothing else does it as hard.

If the goal is a GH pulse without the stress-hormone load, paired with a GHRH analog for the additive effect Law 5 predicts, ipamorelin is the more defensible choice on the selectivity data alone, and it is the one with an actual phase 2 human trial behind it, even a null one.

If oral convenience matters more than injection frequency, neither of these is the answer. That is MK-677, an orally active ghrelin mimetic I ran for 12 weeks with full bloodwork, and it comes with its own metabolic tradeoffs I already covered there.

For the broader category, dosing conventions, legal status by peptide, and how these fit into a stack, the peptides hub is where I am keeping all of it organized.

FAQ

What is ipamorelin?
Ipamorelin is a synthetic 5-amino-acid peptide that activates the ghrelin receptor (GHSR-1a) on the pituitary, triggering a pulse of growth hormone release. It was the first GHRP shown not to raise cortisol or ACTH at GH-releasing doses.

What did the clinical trials actually use?
The pharmacokinetic study used a single 15-minute IV infusion in healthy men. The one outcome-based human trial used IV dosing twice daily for up to 7 days in post-surgical patients. Neither trial ran an oral or long-term daily protocol, so there is no clinical trial basis for extrapolating beyond that.

Is ipamorelin safe?
In the phase 2 surgical trial, the adverse event rate was lower with ipamorelin than with placebo. That is one trial, in a specific patient population, over 7 days. Long-term desensitization and safety data in healthy adults running it for months does not exist in the published literature.

Does ipamorelin stack with CJC-1295?
Mechanically, yes. They activate 2 separate receptors, GHSR-1a and GHRH-R, which is the independent-pathway logic behind why that combination shows up as the standard GHRP-plus-GHRH stack rather than 2 GHRPs paired together.

Who should consider ipamorelin over hexarelin?
Anyone prioritizing a cleaner side-hormone profile over the single largest possible GH pulse, and anyone already accepting that both compounds carry the same FDA and WADA status problems either way.